Steven L. Abrams
Impact in
- Oncology top 10%
- Cancer-related Molecular Pathways
- Cancer Research top 10%
- MicroRNA in disease regulation
Papers in
-
- Melanoma and MAPK Pathways 4
- PI3K/AKT/mTOR signaling in cancer 4
- Protein Kinase Regulation and GTPase Signaling 3
- Protein Tyrosine Phosphatases 2
- Ubiquitin and proteasome pathways 1
- Oncology 2
- HER2/EGFR in Cancer Research 2
- Cytokine Signaling Pathways and Interactions 1
- Co-authors
- Linda S. Steelman (9 shared papers)James A. McCubrey (9 shared papers)Massimo Libra (7 shared papers)Franca Stivala (7 shared papers)Richard A. Franklin (5 shared papers)David M. Terrian (3 shared papers)Patrick M. Navolanic (2 shared papers)Fred E. Bertrand (3 shared papers)
- Journals
- Expert Opinion on Emerging Drugs (2 papers)Cell Cycle (2 papers)Oncogene (1 paper)Blood (1 paper)Leukemia (1 paper)
- Partner nations
- United StatesItalyGermany
In The Last Decade
Steven L. Abrams
9 papers receiving 1.0k citations
Steven L. Abrams's Hit Papers
Peers
Comparison fields: 5 of 82
- Oncology 273
- Cancer Research 148
- Molecular Biology 613
- Hematology 92
- Genetics 72
Countries citing papers authored by Steven L. Abrams
This map shows the geographic impact of Steven L. Abrams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven L. Abrams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven L. Abrams more than expected).
Fields of papers citing papers by Steven L. Abrams
This network shows the impact of papers produced by Steven L. Abrams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven L. Abrams. The network helps show where Steven L. Abrams may publish in the future.
Co-authors
The 25 scholars most cited alongside Steven L. Abrams, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Hit paper breakdown → | 2006 | 551 |
| 2 | 2008 | 189 | |
| 3 | 2008 | 131 | |
| 4 | 2007 | 67 | |
| 5 | 2010 | 48 | |
| 6 | 2009 | 26 | |
| 7 | 2005 | 23 | |
| 8 | 2005 | 9 | |
| 9 | 2006 | 1 |
About Steven L. Abrams
Steven L. Abrams is a scholar working on Molecular Biology, Oncology, Organic Chemistry, Genetics and Pulmonary and Respiratory Medicine, having authored 9 papers that have together received 1.0k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (4 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Protein Kinase Regulation and GTPase Signaling (3 papers), Protein Tyrosine Phosphatases (2 papers), HER2/EGFR in Cancer Research (2 papers), Chronic Myeloid Leukemia Treatments (1 paper), Ubiquitin and proteasome pathways (1 paper) and Cytokine Signaling Pathways and Interactions (1 paper). The work is most often cited by research in Oncology (273 citations), Cancer Research (148 citations), Molecular Biology (613 citations), Hematology (92 citations) and Genetics (72 citations). Steven L. Abrams has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Linda S. Steelman, James A. McCubrey, Massimo Libra, Franca Stivala, Richard A. Franklin, David M. Terrian, Patrick M. Navolanic, Fred E. Bertrand, María Clorinda Mazzarino and Jeffrey L. Salisbury. Their work appears in journals such as Expert Opinion on Emerging Drugs, Cell Cycle, Oncogene, Blood and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.